Compare LRCX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRCX | NVO |
|---|---|---|
| Founded | 1980 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.9B | 212.7B |
| IPO Year | N/A | N/A |
| Metric | LRCX | NVO |
|---|---|---|
| Price | $222.67 | $62.02 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 25 | 10 |
| Target Price | ★ $186.08 | $54.25 |
| AVG Volume (30 Days) | 12.9M | ★ 20.8M |
| Earning Date | 01-28-2026 | 02-04-2026 |
| Dividend Yield | 0.47% | ★ 1.97% |
| EPS Growth | ★ 46.65 | 10.06 |
| EPS | ★ 4.53 | 3.67 |
| Revenue | $19,591,788,000.00 | ★ $49,580,393,058.00 |
| Revenue This Year | $17.52 | $7.25 |
| Revenue Next Year | $14.43 | $0.24 |
| P/E Ratio | $49.21 | ★ $16.45 |
| Revenue Growth | ★ 25.66 | 16.64 |
| 52 Week Low | $56.32 | $43.08 |
| 52 Week High | $229.57 | $93.80 |
| Indicator | LRCX | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 71.40 | 72.64 |
| Support Level | $206.61 | $56.29 |
| Resistance Level | $229.57 | $60.63 |
| Average True Range (ATR) | 7.95 | 1.44 |
| MACD | 2.24 | 0.59 |
| Stochastic Oscillator | 88.13 | 96.28 |
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.